Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit
Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, announced that its CEO Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2025, at 2:30 PM ET. Investors can access the live webcast through Whitehawk's IR website, with the recording remaining available for approximately 30 days after the event.
Whitehawk Therapeutics (NASDAQ: WHWK), un'azienda specializzata in terapie oncologiche focalizzate sui trattamenti ADC per il cancro, ha annunciato che il suo CEO Dave Lennon, PhD, parteciperà a una conversazione informale al TD Cowen 6th Annual Oncology Innovation Summit. L'evento è programmato per il 28 maggio 2025, alle 14:30 ET. Gli investitori potranno seguire la diretta streaming tramite il sito IR di Whitehawk, con la registrazione disponibile per circa 30 giorni dopo l'evento.
Whitehawk Therapeutics (NASDAQ: WHWK), una empresa de terapias oncológicas centrada en tratamientos ADC para el cáncer, anunció que su CEO Dave Lennon, PhD, participará en una charla informal en la 6ª Cumbre Anual de Innovación en Oncología de TD Cowen. El evento está programado para el 28 de mayo de 2025, a las 2:30 PM ET. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de IR de Whitehawk, y la grabación estará disponible aproximadamente 30 días después del evento.
Whitehawk Therapeutics (NASDAQ: WHWK)는 ADC 암 치료에 중점을 둔 종양학 치료제 회사로, CEO Dave Lennon, PhD가 TD Cowen 제6회 연례 종양학 혁신 서밋에서 화상 대화에 참여할 예정이라고 발표했습니다. 행사는 2025년 5월 28일 오후 2시 30분(동부 표준시)에 예정되어 있습니다. 투자자들은 Whitehawk IR 웹사이트를 통해 생중계에 접속할 수 있으며, 녹화 영상은 행사 후 약 30일간 제공됩니다.
Whitehawk Therapeutics (NASDAQ : WHWK), une entreprise spécialisée dans les traitements oncologiques ADC, a annoncé que son PDG Dave Lennon, PhD, participera à une discussion informelle lors du 6e Sommet annuel de l'innovation en oncologie TD Cowen. L'événement est prévu pour le 28 mai 2025 à 14h30 ET. Les investisseurs pourront accéder à la diffusion en direct via le site IR de Whitehawk, l'enregistrement restant disponible environ 30 jours après l'événement.
Whitehawk Therapeutics (NASDAQ: WHWK), ein Unternehmen für onkologische Therapien mit Schwerpunkt auf ADC-Krebsbehandlungen, gab bekannt, dass sein CEO Dave Lennon, PhD, an einem Gespräch beim 6. jährlichen TD Cowen Oncology Innovation Summit teilnehmen wird. Die Veranstaltung findet am 28. Mai 2025 um 14:30 Uhr ET statt. Investoren können den Live-Webcast über die IR-Website von Whitehawk verfolgen, die Aufzeichnung ist etwa 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-td-cowen-6th-annual-oncology-innovation-summit-302461639.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
When is Whitehawk Therapeutics (WHWK) presenting at the TD Cowen Oncology Summit 2025?
Who will represent Whitehawk Therapeutics (WHWK) at the TD Cowen Oncology Summit?
How can investors access Whitehawk Therapeutics' (WHWK) presentation at the TD Cowen Summit?
What is Whitehawk Therapeutics' (WHWK) main business focus?
